Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

NEW DRUGS

FDA Approves Tepmetko for Metastatic NSCLC and MET Exon 14 Skipping Alterations

JHOP - February 2021 Vol 11, No 1 - FDA Updates, Lung Cancer
Download pdf

On February 3, 2021, the FDA accelerated the approval of oral tepotinib (Tepmetko; EMD Serono) for adults with metastatic non–small-cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping alterations. This approval is for treatment-naïve patients as well as for patients who have received previous therapy. Tepotinib is the first MET inhibitor approved by the FDA and should be selected for treatment based on the presence of METex14. The FDA has granted tepotinib breakthrough therapy and orphan drug designations.

METex14 skipping occurs in approximately 3% to 4% of NSCLC cases, and patients with this aggressive lung cancer are often elderly and face a poor clinical prognosis,” said Paul K. Paik, MD, VISION lead investigator and Clinical Director, Thoracic Oncology

Service, Memorial Sloan Kettering Cancer Center, New York, NY. “There is a pressing need for targeted treatments that have the potential to generate durable anti-tumor activity and improve the lives of patients with this challenging disease.”

“The availability of a new precision medicine for NSCLC with METex14 skipping alterations advances patient access to targeted treatment and underscores the importance of routine comprehensive biomarker testing for patients with this challenging cancer,” said Andrea Ferris, LUNGevity President and CEO.

The FDA approved tepotinib based on data from the phase 2 clinical trial VISION, a multicenter, nonrandomized, open-label, multicohort study that enrolled 152 patients with advanced or metastatic NSCLC and METex14 skipping alterations.

The study included 69 treatment-naïve patients and 83 patients who have received previous therapy. All patients received monotherapy with tepotinib 450 mg orally once daily until disease progression or until unacceptable adverse events. The main efficacy outcome measures were overall response rate (ORR) and duration of response (DOR).

Among the 69 treatment-naïve patients, the ORR was 43% (95% confidence interval [CI], 32%-56%), with a median DOR of 10.8 months (95% CI, 6.9-not estimable). Among the 83 patients who received previous treatment, the ORR was 43% (95% CI, 33%-55%), with a median DOR of 11.1 months (95% CI, 9.5-18.5).

The most common (≥20% of patients) adverse reactions were edema, fatigue, nausea, diarrhea, musculoskeletal pain, and dyspnea. Tepotinib can also cause interstitial lung disease, hepatotoxicity, and embryo-fetal toxicity.

The recommended dose of tepotinib tablets is 450 mg orally once daily.

This approval was based on ORR and DOR data. Continued approval may be contingent on the verification of clinical benefit in confirmatory clinical trials.

Related Items
Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Updates
Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Updates
Pylarify Second Radioactive Imaging Drug FDA Approved for PSMA-Positive Prostate Cancer
Web Exclusives published on October 5, 2021 in FDA Updates
Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC
Phoebe Starr
Web Exclusives published on October 4, 2021 in Lung Cancer, ASCO Highlights
Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma
JHOP - August 2021 Vol 11, No 4 published on August 17, 2021 in FDA Updates
FDA Approved Truseltiq for Metastatic Cholangiocarcinoma with the FGFR2 Biomarker
JHOP - August 2021 Vol 11, No 4 published on August 17, 2021 in FDA Updates
2021 Midyear Review: Non–Small-Cell Lung Cancer
2021 Midyear Review: Non–Small-Cell Lung Cancer published on August 11, 2021 in Lung Cancer
FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma
Web Exclusives published on August 10, 2021 in FDA Updates
FDA Approves Avapritinib for Advanced Systemic Mastocytosis
Web Exclusives published on August 10, 2021 in FDA Updates
Pembrolizumab plus Lenvatinib Combination Receives Regular Approval for Advanced Endometrial Carcinoma
Web Exclusives published on August 10, 2021 in FDA Updates
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.